Avalo Therapeutics Inc
AVTX
Market Cap$14.85M
Close$
$-1.45
110.9% downside
Current Fair Value
110.9% downsideOvervalued by 110.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.85 Million |
|---|---|
| Enterprise Value | $7.44 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.11 |
| Beta | 0.0 |
| Outstanding Shares | 1,034,130 |
| Avg 30 Day Volume | 128,017 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.47 |
|---|---|
| PEG | 2.81 |
| Price to Sales | 13.25 |
| Price to Book Ratio | 1.89 |
| Enterprise Value to Revenue | 3.86 |
| Enterprise Value to EBIT | -0.32 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Avalo Therapeutics Inc
31 employeesCerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that ad...